Rol' sinteticheskogo liganda PPARy-rosiglitazona v patogeneticheskom lechenii sakharnogo diabeta 2 tipa

Cover Page

Abstract


Росиглитазон (Авандия) обеспечивает значительное снижение глюкозы плазмы натощак, HbAlc
и уровня постпрандиальной гликемии. Достигнутая компенсация углеводного обмена сохраняется длительное время. Росиглитазон эффективен в качестве монотерапии и в комбинации с метформином, производными сульфонилмочевины и с инсулином, как при однократном, так и при двукратном приеме вне зависимости от приема пищи. Росиглитазон эффективен как у больных СД 2
типа, имеющих ожирение, так и без ожирения. Росиглитазон улучшает функцию бета-клеток и
тем самым способен замедлять прогрессирование заболевания. Воздействуя практически на все компоненты метаболического синдрома, росиглитазон способен снижать риск развития и прогрессирования сердечно-сосудистых заболеваний.

About the authors

Irina Vladimirovna Kononenko

Endocrinology Research Centre, Moscow

Olga Mikhailovna Smirnova

Endocrinology Research Centre, Moscow

References

  1. Albert М.А., Ridker P.M. The role of C-reactive protein in cardiovascular disease risk.//Current Cardiology Reports. - 1999. - V. 1. - P. 99-104.
  2. Beales P., Liddi R., Giorgini A. et al. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. / / Eur J Pharmacol. - 1998. - Vol. 357. - P. 221 - 225.
  3. Beales P., Rosignoli G., Liddi R. et al. Rosiglitazone reduces diabetes incidence in the NOD mouse. / / Diabetes Res Clin Pract. - 2000. -Vol. 50 (Suppl. 1).-P. 1518.
  4. Brunzell J., Cohen B.R., Kreider M. et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes.// Diabetes. - 2001. - V . 50 (Supplement 2). A l 4 1 .
  5. Beebe K.L., Patel J. Rosiglitazone is effective and well tolerated in patients > 65 years with type 2 diabetes.// Diabetes. - 1999. - V.48 (Supplement 1). A l 1 1.
  6. Banerji M., Lebovitz H.E., Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus.// Diabetes. - 2001. - V.50 (Supplement 2). А90
  7. Charbonnel В., Lonnqvist F., Jones N.P. et al. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients.// Diabetes. - 1999. - V. 48 (Supplement 1). АП4-А115.
  8. Clifford J Bailey, Caroline Day. Thiazolidinediones today. / / Br J of Diabetes Vase Dis. - 2001. - Vol. 1 Is. 1. - H.7-13.
  9. Cranmer H., Jones N.P., Patwardhan R. Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.// Diabetologia. - 1999. - V. 42 (Supplement 1). A228.
  10. DeFronzo R.A.:Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia - 1992; - 35; - P.389 - 397.
  11. DeFronzo R.A. Lilly Lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. / / Diabetes. - 1988. - Vol. 37. - P. 667-687.
  12. DeFronzo R.A, Gunnarsson R, Bjorkman O, Olsson M. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. / / J Clin Invest. - 1985.-Vol.76. - P. 149-155.
  13. Fonseca V.A., Biswas N., Salzman A. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycemia in patients with type 2 diabetes.// Diabetes. 1999. V. 48 (Supplement 1). A l 00.
  14. Freed M., Fuell D., Menci L. et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes.// Diabetologia. - 2000. - V. 43 (Supplement 1). A267.
  15. Grunberger G., Weston W.M., Patwardhan R. et al. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes.// Diabetes. - 1999. - V . 48 (Supplement 1). A102.
  16. GlaxoSmithKline. Data on file. 2001.
  17. Gomis R., Jones N.P., Vallance S.E. et al. Low-dose rosiglitazone provides additional glycemic control when combined with sulfonylureas in type 2 diabetes (T2D). / / Diabetes. - 1999. - V. 48 (Supplement 1). A63.
  18. 8. Greenberg A., Haffner S., Weston W. et al. Rosiglitazone reduces Creactive protein, a marker of systemic inflammation in type 2 diabetic patients.// Diabetologia. - 2001. - V. 44 (Supplement 1). A222.
  19. Haring H.U.:Molecular biology of insulin action and resistance. In: E. Standi (Ed.): Perspectives of the hyperinsulinaemia/insulin resistance syndrome in NIDDM: From pathophysiology to clinical implications. MMV Medizin Verlag, Munchen -1 990. - V.9 - P.20.
  20. Hennes M.M., Shrago E., Kissebah A.: Receptor and postreceptor effects of free fatty acids (FFA) on hepatocyte insulin dynamics. Int. J. Obesity - V.I 4 - 1990-P.831 - 41
  21. Hsueh WA, Law RE. Arterioscler Thromb Vase Biol. 2001 ;21:1 891 -1895
  22. Insulin Resistance. Editer by Gerald M.Reaven.1999. Humana Press. Chapter 9. 170-173.
  23. Kim Y.-B., Ciaraldi T.P., Kong A. et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p i 10b protein levels in skeletal muscle of type 2 diabetic subjects. //Diabetes. - Feb 2002. - V. 5 1 .
  24. Kreider M., Miller E., Patel J. Rosiglitazone is safe and well tolerated as monotherapy or cimbination therapy in patients with type 2 diabetes mellitus (T2DM).// Diabetes. - 1999. - V. 48 (Supplement 1). A l 17.
  25. Lebovitz H.E., Dole J.F., Patwardhan R. et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. / / J Clin Endocrinol Metab. - 2 0 0 1 . - V . 86.-P.280-288.
  26. Miyazaki Y et al. J Clin Endocrinol Metab. - 2002 - V.87 - P.2784-2791
  27. Miyazaki Y., Matsuda M., Mahankali A. et al. Mechanisms of glucoselowering effect by rosiglitazone in patients with type 2 diabetes.// Diabetes - 2001 - V. 50 (Supplement 2). A126.
  28. Miyazaki Y., Mahankali A., Matsuda M. et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.//Diabetes Care - 2001 - V. 24(4) - P. 710-719.
  29. Marceille J.R., Goins A.J., Soni R. et al. Chronic heart failure - related interventions after starting rosiglitazone in patients receiving insulin.// Pharmacotherapy - 2004 - V.24( 10) - P. 1317-1322.
  30. Oakes N.D., Kennedy C.J., Jenkins A.B. et al. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. / / Diabetes. - 1994. - V. 43. - P. 1203-1210. 35. 36. 37.
  31. Park K.-S., Ciaraldi T.P., Abrams-Carter L. et al. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. / / J Clin Endocinol Metab. - 1998. - V. 83. - P.l 636-1643.
  32. Philips L.S., Grunberger G., Miller E. et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in with type 2 diabetes. //Diabetes Care. - 2001. - V. 24. - P.308-315.
  33. Page R.L. II, Gozansky W.S., Ruscin J.M. Possible heart failure exacerbation associated with rosiglitazone and literature review. / / Pharmacotherapy. - 2003. - V. 23(7). - P. 945-954.
  34. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus / / Diabetes Care. - 1997. - Vol.20. - P. 219-220
  35. Reaven G.M. The fourth Musketeer - from Alexandre Dumas to Claude Bernard. / / Diabetologia. - 1995. - Vol. 38. - P. 3 - 13.
  36. Reaven G.M.: Banting Lecture 1 988: role of insulin resistance in human disease. Diabetes 1988; 37; 1595-1607.
  37. Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. / / Ann. Rev. Dev. Biol. - 2000. - V. 16. - P. 145-171.
  38. Ross R. Atherosclerosis - an inflammatory disease. / / New England Journal of Medicine. - 1999. - V. 340. - P. 115-126.
  39. Rachman J., Payne M.J., Levy J.C. et al. Changes in amylin and amylinlike peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.//Diabetes Care. - 1 998. - V.21. - P.810-816.
  40. Raskin P., Dole J.F., Rappaport E.B. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (T2D). / / Diabetes. - 1999. - V. 48 (Supplement 1). A94.
  41. Shulman G.I., Rothman D.L., Jue T. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. - 1990. - V.322 - P.223-228.
  42. SmithKline Beecham. Avandia prescribing information. 2001.
  43. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.//Diabetes. - 1998. - V.47. - P. 507-514.
  44. Stewart M., Jones N.P., Kreider M. et al. Combined effects of rosiglitazone and atorvastatin on the dyslipidemia associated with type 2 diabetes.// Diabetologia. 2001. V. 44 (Supplement 1). A222.
  45. Salzman A., Patel J. Rosiglitazone therapy is not associated with hepatotoxicity.// Diabetes. 1999. V. 48 (Supplement 1). A95.
  46. Unger R.H. Lipotoxity in the pathogensis of obesity-dependent NIDDM. Genetic and clinical implications. / / Diabetes. - 1995. - Vol. 44. - P. 863-870.
  47. Uemura S., Matsushita H., Li W. et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. / / Circulation Research. - 2001. - V.88. - P. 1291-1298.
  48. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. / / Diabetes. - 1995. - V.44. - P. 1249-1258.
  49. Vongthavaravat V, Bernardo L.W., Jorge N.W. et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. / / Curr Med Res Opin. - 2002. - V. 18(8). - P. 456-461.
  50. Werner A.L., Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. / / Pharmacotherapy. - 2001. - V. 21(9). - P. 1082-1099.
  51. Yoshinori Miyazaki, Helen He. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. / / Diabetes. - 2003. - Vol. 52 (8). - P. 1943-1950.
  52. Yoshimoto T et al. Atherosclerosis. - 1999. - V. 145 - P.333-340.
  53. Young P.W., Buckle D.R., Cantello B.C. et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BPL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferators-activated receptor gamma.//Journal of Pharmacology and Experimental Therapeutics. - 1998. - V. 284. - P. 751-759.
  54. Young P.W., Cawthorne M.A., Coyle P.J. et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. / / Diabetes. - 1995. -V.44. - P.1087-1092.

Statistics

Views

Abstract - 706

PDF (Russian) - 270

Cited-By


PlumX

Dimensions


Copyright (c) 2005 Kononenko I.V., Smirnova O.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies